Navigation Links
Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
Date:5/20/2008

HAE:TSX

MONTREAL, May 20 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announces that Gilles Lemieux, Corporate Secretary, will present at Busines$ Meets Finance at the Montreal Sheraton Centre on May 20, 2008 at 2:35 p.m.

About Busines$ Meets Finance

Busines$ Meets Finance is a conference organized by the Toronto Stock Exchange and the Montreal law firm Heenan Blaikie designed to foster alliances between investors and Quebec small and medium size businesses. The conference will be attended by leading North American private equity and merchant banking firms from the United States and the rest of Canada.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-look
'/>"/>

SOURCE Haemacure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
3. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
4. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
5. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
6. Haemacure Reports on its annual general and special meeting of shareholders
7. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
8. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
9. Haemacure financing receives shareholder consent - Series B Warrants are amended
10. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... New minimally-invasive pro...inus pain and decrease the risk of sinusitis, or s...e physicians of the Atlanta Snoring Institute. Te...and congested sinuses without having to remove any... The advantages of these breakthroughs in treating...
(Date:11/25/2009)...,, VANCOUVER,Nov.25/PRNewswire/-- AdamDreamHeal...ealingintentionschangesthephysiologyofsomeoneatadi...atatimeunknowntoavolunteerwhowasmonitoredbyaquanti...AandCanada. ,, OnNovember8inVancouver,B.C.Adami...ent.Tofocusintentions,Adamcreatedavideoclipofaspec...
(Date:11/24/2009)... Eating high amounts of salt is linked to a signi... disease, states a paper published today in the B...ied out jointly by the World Health Organization,s...University of Warwick and University Hospital in C...ion Excellence Centre in Hypertension based at the...
(Date:11/24/2009)...(Boston) Researchers from Boston University Schoo...medical Engineering Department have identified a n...distinguish between cancer and normal cells with a...earchers have developed a new computational strate...key biological pathways (molecular circuits) that ...
(Date:11/24/2009)...,, DALLAS,Nov.24/PRNewswire-USNewswire/--TheBay...rofoneofthelargestcancerclinicaltrialscooperativeg...heNationalCancerInstitute,SouthwestOncologyGroupco...s,andtoimprovethequalityoflifeforcancersurvivors. ...eradditional,importantclinicaltrialstocancerpatien...
Breaking Medicine News(10 mins):Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 2Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 3Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 4Health News:Intriguing Scientific Results from World's Largest Intention Healing Project: DreamHealer 2Health News:High salt intake linked to strokes and cardiovascular disease 2Health News:Researchers identify proteins in lung cancer cells that may provide potential drug targets 2Health News:Baylor Sammons Cancer Center Joins One of Nation's Largest Cancer Clinical Trials Groups 2
... Nuvilex, Inc. (OTC Bulletin Board: NVLX.OB), form...mer products company with a portfolio of aesthetic...oducts, announced today that it intends to reduce ...lthy glucose metabolism, to raise customer awarene...
...nts have access to most comprehensive Spanish-lang.... , April 8 CVS Caremark (NYSE: CVS ) today an...k.com. The Web site makes it easier for Spanish-s...iption benefits. Plan participants can access the...
...Bowl MVP Eli Manning , who serves as the March of...d business and corporate leaders on Monday, April ...es. Devin Wenig, CEO, Thompson Reuters, and a memb...s Co-Anchor, Maurice DuBois , emceed the progra...
...althfinder.gov has long been recognized as a key r...fit health prevention information on the Internet....edible information catalogued on the site. But it ...nted. , Washington D.C. (...
...il 8 InfuSystem (OTC Bulletin Board: INHI; INHI...sion pumps and associated clinical services, today... on its Term Loan in addition to its normal quarte... million, to $24.1 million. The Term Loan was a r...
...arks on intentions for good nutrition but lack kno...April 8 It,s no surprise that with the current ec...at comes from their home(1) and healthy eating is ... researchers found that, in general, households a...
Other Medicine News:Health News:Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign 2Health News:Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign 3Health News:Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign 4Health News:Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign 5Health News:CVS Caremark Launches Spanish Version of Caremark.com 2Health News:CVS Caremark Launches Spanish Version of Caremark.com 3Health News:Eli Manning and Top Corporate Leaders Rally to Help Save Babies 2Health News:healthfinder.gov Adds New Interactive Features to Its Web Site 2Health News:InfuSystem Pays Down Term Loan by $6.1 Million Year-to-Date 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 3
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--AnadysPharmaceutica...entatthe21stAnnualPiperJaffrayHealthcareConference....TheconferenceisbeingheldatTheNewYorkPalaceHotel.S...rofAnadys,willprovideanoverviewofAnadysanditsclini...orporatepresentationwillbesimultaneouslywebcastand...
(Date:11/24/2009)...ON,Calif.,Nov.24/PRNewswire-FirstCall/--ThoratecCo...dmechanicalcirculatorysupporttherapiestosave,suppo...ticipatinginthe21stAnnualPiperJaffrayHealthCareCon...cutivevicepresidentandchieffinancialofficer,willpr...ernStandardTime(5:30a.m.,PacificStandardTime). ,...
(Date:11/24/2009)...N.C.,Nov.24/PRNewswire/--PharmaceuticalInstitute,a...epharmaceuticalandbiotechindustry,todayannouncedth...Thenew HospitalMarketplace e-courseisthenewestaddi...ries,acomprehensiveseriesofe-coursesdesignedtofill...owledgeforcommercialprofessionals. ,, Thenewthr...
Breaking Medicine Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 1 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 3 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 4 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 5 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 6 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 7 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 8 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 9Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 1Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 1Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 3Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 4
...ma Continues Its Success with Positive Phase IIa C...irm Potential New Application of Key,Product in AM... 9, 2007-AM-Pharma B.V., the,biopharmaceutical com...ious and inflammatory diseases, today announced th...ine Phosphatase (AP) trial,for patients with ulcer...
...ND, VA., July 9 /CNW/ - Insmed Inc. (NASDAQ:INSM),...opment and approval,of drugs for the treatment of...y announced that it will present at this,week,s C...tunities Conference in New York City. , The con... in New,York City, will run from Tuesday, July 10...
Other Medicine Technology:AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
Soft-Touch Timeter® 8 LPM Flowmeter With 1 Power take Off
Soft-Touch Timeter® 8 LPM Flowmeter
Oxygen Dial Flowmeters - Chemetron
... offers a complete line of flowmeters, available i...lable in a variety of calibrations to best suit yo...specific to the gas in use, the Amvex Flowmeter is... the U with I. For Power Take-Off add PT to the en...
Medicine Products: